Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1531-1535

  Mergenhagen, Kari A ^a,b   Pasko, Mary T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Daptomycin; Endocarditis; Methicillin resistant Staphylococcus aureus; Vancomycin

Indexed keywords

CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; VANCOMYCIN;

ADULT; AFRICAN AMERICAN; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; BRAIN ABSCESS; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPENIA; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENDOCARDITIS; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; MITRAL VALVE; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 34548146011     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K071     Document Type: Article

References (25)

1. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother 2006;7:1381-97.
2. Drees M, Boucher H. New agents for Staphylococcus aureus endocarditis. Curr Opin Infect Dis 2006;19:544-50.
3. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
4. Levine D. Daptomycin for infective endocarditis. Curr Infect Dis Rep 2006;8:263-4.
5. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347-52.
6. Andres E, Kurtz JE, Maloisel F. Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature. Clin Lab Haematol 2002;24:99-106.
7. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434.
8. Rocha JL, Kondo W, Baptista MI, Da Cunha CA, Martins LT. Uncommon vancomycin-induced side effects. Braz J Infect Dis 2002;6:196-200.
9. Pai MP, Mercier R-C, Koster SA. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann Pharmacother 2006;40:224-8. Epub 24 Jan 2006. DOI 10.1345/aph.1G436
10. Morris A, Ward C. High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit. J Infect 1991;22:217-23.
11. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
12. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005;55:283-8.
13. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004;48:63-8.
14. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007;27:227-49.
15. Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 2005;34:69-71.
16. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006;58:273-80.
17. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002;35:1018-20.
18. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004;38:864-70.
19. Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005;37:946-9.
20. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000;46:775-84.
21. Viale P, Scolari C, Colombini P, Cristini F, Cadeo B, Pagani L. Sequential regimen for early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA), unresponsive to standard antibiotic therapy: a case report. J Chemother 2002;14:526-9.
22. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8.
23. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005;25:253-64.
24. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
25. Smith JW, Chalupa P, Shabaz Hasan M. Infectious arthritis: clinical features, laboratory findings and treatment. Clin Microbiol Infect 2006;12:309-14.